This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and rais

Company Announcement COPENHAGEN, Denmark; October 7, 2026 –  Genmab A/S  (Nasdaq: GMAB)  Today, Genm

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and

Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in r

ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the

Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The late

The Danish company said the Epkinly drug helped extend the time patients with a common type of lymph

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improveme

[url="]Genmab A/S[/url](Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline resul

Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today positive topline results from the Ph

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrat

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NY

Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price

Treatment with Rina-S 120 mg/m² every three weeks demonstrated a clinically meaningful objective res

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ

Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three wee

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced results from Part C

As of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfo

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2

Genmab A/S NASDAQ: GMAB expects a pivotal fourth quarter, with Phase III readouts planned for three

Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) hit a new 52-week high during mid-day trad

Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced t

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and

Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increas

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price

Genmab (NASDAQ:GMAB) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billio

 Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.

Wall Street analysts updated ratings and price targets for top companies, including Robinhood, Westl

AVAV: 31% | AeroVironment shares are trading higher after the company reported better-than-expected

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street ana

ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse ev

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrade

U.S. stock futures were higher this morning, with the Dow Jones futures gaining over 50 points on Tu

  On Friday, 68 companies reached new 52-week highs.

  During Monday's session, 50 stocks hit new 52-week highs.

Upgrades

  On Tuesday, 951 companies hit new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.

Upgrades